当前位置： SCI文献检索 > Ginekologia Polska期刊下所有文献 > [Ultrasound evaluation of NO-donor (L-arginine) therapy for intrauterine growth retardation].

[Ultrasound evaluation of NO-donor (L-arginine) therapy for intrauterine growth retardation].

Abstract：

UNLABELLED:There are many methods of the growth restriction therapy, but the results are still not satisfactory. Actually, we are conducting a project which main conception is based on the use of the NO donor (L-arginine) in growth retardation therapy. This amino acid is an effective NO donor and has a vasodilating effect on the vessels and anti-aggregation effect on platelets, which plays a great role in improving feto-maternal blood flow. The main aim of this paper is the ultrasound evaluation of the effectiveness of NO-donor (L-arginine) therapy for intrauterine growth retardation based on biometrical measurements (estimated fetal weight) compared with newborns weight estimation. METHODS:The investigated group comprised two groups of pregnant women with ultrasonographically diagnosed intrauterine growth retardation (biometry <10th percentile for the gestation age): --78 patients were treated by L-arginine 3 g daily p.o. in 20 days period. --30 patients not treated (no agreement for therapy) as controls. RESULTS:Ultrasound estimation of fetal weight at the start and at the end of the treatment showed a mean value increase of 642 g (SE 90g) using Shepard method and 648g (SE 94g) using Hadlock method respectively. Comparing not treated group there was assessed a mean value increase of 395 g (SE 77 g) using Shepard method and 404g (SE 82g) using Hadlock method respectively. There is statistical significant difference comparing an estimated fetal weight in both methods: p = 0.008 for Shepard calculation and p = 0.012 for Hadlock calculation. There was analyzed newborn weight also--in a treated group mean value was at 2823 g and in not treated group mean value was at 2495 g. There was no significant difference found but a positive tendency for treated group newborns weight is visible. In the treated group number of the growth retarded newborns was at 29% and in the not treated group was at 73%. There was found a significant difference comparing both newborns groups at p < 0.05. CONCLUSIONS:The ultrasound evaluation of the estimated fetal weight and after-birth weight estimation of the newborns showed an increased dynamic of the fetal development in the L-arginine treated group of pregnant women comparing to the not treated group. The ultrasound evaluation of the estimated fetal weight is a good diagnostic tool for properly monitoring the effectiveness of treatment with L-arginine for growth retarded fetuses.

journal_name

Ginekol Pol

journal_title

Ginekologia polska

authors

Sieroszewski P,Suzin J,Karowicz-Bilińska A

keywords:

subject

Has Abstract

pub_date

2004-12-01 00:00:00

pages

913-8

issue

eissn

0017-0011

issn

2543-6767

journal_volume

pub_type

杂志文章

在线工具

[Ultrasound evaluation of NO-donor (L-arginine) therapy for intrauterine growth retardation].